Why the study?
Do GLP-1 receptor agonists, SGLT-2 inhibitors, or DPP-4 inhibitors reduce the risk of severe COPD exacerbations compared with sulfonylureas in patients with COPD and type 2 diabetes?
Do GLP-1 receptor agonists, SGLT-2 inhibitors, or DPP-4 inhibitors reduce the risk of severe COPD exacerbations compared with sulfonylureas in patients with COPD and type 2 diabetes?
GLP-1 receptor agonists and SGLT-2 inhibitors may reduce the risk of severe COPD exacerbations in patients with concurrent type 2 diabetes compared to sulfonylureas.
Answers are grounded in this paper and cite their sources.
May support preferential use of GLP-1 agonists or SGLT2 inhibitors over sulfonylureas in COPD with diabetes; leaves open confirmation by RCTs.
In this population based study, GLP-1 receptor agonists and SGLT-2 inhibitors were associated with a reduced risk of severe exacerbations compared with sulfonylureas in patients with chronic obstructive pulmonary disease and type 2 diabetes. DPP-4 inhibitors were not clearly associated with a decreased risk of chronic obstructive pulmonary disease exacerbations.
No takes yet. Share an insight, caveat, or question.
Pradhan et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: